Peptidic vaccines: The new cure for heart diseases?
Autor: | Belinda Carrión-Chavarría, Noé Francisco Garay-Gutiérrez, Iván Alfredo Mijares-Rojas, Carlos Enrique Guerrero-Beltrán, Gustavo Salgado-Garza |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Heart disease medicine.medical_treatment Disease Autoantigens Renin-Angiotensin System 03 medical and health sciences 0302 clinical medicine Immune system Medicine Animals Humans Intensive care medicine Pharmacology business.industry PCSK9 Cancer Immunotherapy medicine.disease Plaque Atherosclerotic 030104 developmental biology Cardiovascular Diseases 030220 oncology & carcinogenesis Vaccines Subunit Preventive intervention Disease prevention Endothelium Vascular business |
Zdroj: | Pharmacological research. 164 |
ISSN: | 1096-1186 |
Popis: | Cardiovascular disease continues to be the most common cause of death worldwide. The global burden is so high that numerous organizations are providing counseling recommendations and annual revisions of current pharmacological and non-pharmacological treatments as well as risk prediction for disease prevention and further progression. Although primary preventive interventions targeting risk factors such as obesity, hypertension, smoking, and sedentarism have led to a global decline in hospitalization rates, the aging population has overwhelmed these efforts on a global scale. This review focuses on peptidic vaccines, with the known and not well-known autoantigens in atheroma formation or acquired cardiac diseases, as novel potential immunotherapy approaches to counteract harmful heart disease continuance. We summarize how cancer immunomodulatory strategies started novel approaches to modulate the innate and adaptive immune responses, and how they can be targeted for therapeutic purposes in the cardiovascular system. Brief descriptions focused on the processes that start as either immunologic or non-immunologic, and the ultimate loss of cardiac muscle cell contractility as the outcome, are discussed. We conclude debating how novel strategies with nanoparticles and nanovaccines open a promising therapeutic option to reduce or prevent cardiovascular diseases. |
Databáze: | OpenAIRE |
Externí odkaz: |